选择性雄激素受体调节剂GSK2849466A对去卵巢雌激素缺乏大鼠压力性尿失禁及膀胱活动的影响
本研究在双侧卵巢切除诱导的压力性尿失禁大鼠模型中,评估选择性雄激素受体调节剂GSK2849466A对尿道控尿机制的作用。结果显示低剂量SARM恢复尿道基础压,高剂量SARM逆转尿道基础压和喷嚏时尿道反应幅度下降,更有效防止喷嚏时尿失禁,且不影响膀胱功能;SARM可能比双氢睾酮更有效治疗压力性尿失禁。
要点
- 卵巢切除6周后大鼠出现喷嚏时压力性尿失禁。
- 高剂量SARM逆转尿道基础压和喷嚏时尿道反应幅度下降,有效防漏尿。
- SARM不影响膀胱功能,可能优于双氢睾酮。
核心结论
- SARM治疗可能比DHT更有效治疗压力性尿失禁,且不影响膀胱功能。
研究设计与样本
- 雌性Sprague-Dawley大鼠双侧卵巢切除后分为五组:假手术组、载体治疗OVX组、低剂量SARM组(0.005 mg/kg/day,口服)、高剂量SARM组(0.03 mg/kg/day,口服)和DHT组(1 mg/kg/day,皮下)。
- SARM治疗4周或DHT治疗3周(OVX后6周)后评估喷嚏诱导的控尿反射、漏尿点压力和连续膀胱测压,并进行尿道组织学分析。
主要发现
- OVX后6周显著损害尿道控尿功能,诱导喷嚏时压力性尿失禁。
- 低剂量SARM恢复尿道基础压而不影响喷嚏时尿道反应幅度,部分逆转OVX诱导的喷嚏时压力性尿失禁。
- 高剂量SARM逆转尿道基础压和喷嚏时尿道反应幅度的下降,更有效防止喷嚏时压力性尿失禁。
- DHT仅恢复喷嚏时尿道反应幅度而不影响尿道基础压,部分防止OVX诱导的喷嚏时压力性尿失禁。
- 高剂量SARM诱导尿道周围横纹肌和平滑肌肥大;SARM治疗不影响假手术或OVX大鼠的膀胱功能。
临床怎么用
- SARM可能作为压力性尿失禁的潜在治疗选择,尤其针对尿道平滑肌和横纹肌功能增强。
- SARM治疗不影响膀胱功能,可能具有较好的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the effect of a selective androgen receptor modulators (SARMs) on the urethral continence mechanisms in a rat model of stress urinary incontinence (SUI) induced by bilateral ovariectomy (OVX). MATERIALS AND METHODS: Female Sprague-Dawley rats with bilateral OVX were used. Rats were divided into five groups; sham operated, vehicle-treated OVX, low-dose SARM-treated OVX (GSK2849466A: 0.005 mg/kg/day, per os [p.o.]), high-dose SARM-treated OVX (GSK2849466A: 0.03 mg/kg/day, p.o.) and dihydrotestosterone (DHT)-treated OVX (1 mg/kg/day, subcutaneous) groups. After 4 weeks of SARM treatments or 3 weeks of DHT treatment (6 weeks after OVX), rats were subjected to evaluation of the sneeze-induced continence reflex using microtransducer-tipped catheter methods, sneeze-induced leak-point pressure, and continuous cystometry measurements, followed by histological analyses of urethral tissues. RESULTS: (i) OVX significantly impaired urethral continence function after 6 weeks to induce SUI during sneezing. (ii) Low-dose SARM treatment restored urethral baseline pressure (UBP) without affecting the amplitude of urethral response during sneezing (A-URS), partially reversing OVX-induced SUI during sneezing. (iii) High-dose SARM treatment reversed decreases in both UBP and A-URS, more effectively preventing SUI during sneezing. (iv) DHT treatment only restored A-URS without affecting UBP, partially preventing OVX-induced SUI during sneezing. (v) The high-dose SARM treatment induced hypertrophy of the striated and smooth muscle around the urethra. (vi) SARM treatment did not affect bladder function in sham or OVX rats. CONCLUSION: Treatment with SARMs could be a more effective modality for the treatment of SUI than DHT, without affecting bladder function, by enhancing smooth- and striated muscle-mediated urethral function under stress conditions such as sneezing.
引用
- Kadekawa K, Kawamorita N, Shimizu T, et al. Effects of a selective androgen receptor modulator (SARM), GSK2849466A, on stress urinary incontinence and bladder activity in rats with ovariectomy-induced oestrogen deficiency. BJU Int. 2020. PMID: 32011085. doi:10.1111/bju.15022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。